CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings

Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings

CuraTeQ Biologics receives positive opinion for biosimilar Dazublys from EMA

Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein

Fortis Healthcare launches Fortis Institute of Genomic Medicine

Genomics is transforming the future of modern medicine and treatment modalities across specialties

Neuberg Diagnostics and Magnum Imaging inaugurates diagnostics centre in Trichy

Women Health Card was launched exclusively for women health workers of the Tiruchirappalli City Corporation

Cipla receives USFDA approval for Protein-bound Paclitaxel for Injectable Suspension

Protein-bound Paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas

Health Minister inaugurates Second AIIMS Oncology Conclave at NCI-AIIMS, Jhajjar

AstraZeneca plans US$ 570 million investment in Canada

700 new scientific and high-skilled jobs to be created in Greater Toronto Area, investing to execute more than 210 AstraZeneca global clinical studies

Bayer’s pharma growth strategy progressing well as pipeline advances

Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid

Kwality Pharmaceuticals receives approval for Tamoxifen 20mg Tablet in South Africa

This approval is a significant achievement in expanding the availability of this critical therapeutic,

Enhertu approved in China as first HER2-directed therapy for patients with HER2-mutant metastatic NSCLC

Enhertu demonstrated clinically meaningful efficacy in previously treated patients